Acorn Capital Advisors, LLC
Acorn Capital Advisors, LLC reported 20 US-listed holdings worth $366.5 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: CG Oncology Inc. (21.9%), Urogen Pharma Ltd (16.8%) and Trevi Therapeutics Inc. (10.9%). Against the quarter before, it opened 1 position, added to 4, trimmed 2 and sold out of 3.
The 14 largest of its 20 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +75.6% over the 5 quarters to 31 March 2026, against +11.0% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Engene Therapeut ENGN$2.2 million
Added to 4
- Karyopharm Therapeutics Inc. KPTI+1.2 million shares · +427%
- Jade Biosciences Inc. JBIO+200,000 shares · +25%
- Aura Biosciences Inc. AURA+333,333 shares · +56%
- Jasper Therapeutics Inc. JSPR+26,667 shares · +2%
Trimmed 2
- Bioatla Inc. BCAB-5.3 million shares · -98%
- Q32 Bio Inc. QTTB-98,881 shares · -31%
Sold out of 3
- Terns Pharmaceuticals Inc. TERN$92.1 million last quarter
- Cardiff Oncology Inc. CRDF$2.9 million last quarter
- X4 Pharmaceuticals Inc.$966,583 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| CG Oncology Inc. CGON | 1.1M | $80.4 million | 21.94% | +999 |
| Urogen Pharma Ltd URGN | 1.7M | $61.6 million | 16.80% | no change |
| Trevi Therapeutics Inc. TRVI | 2.1M | $40.0 million | 10.92% | no change |
| Candel Therapeutics Inc. CADL | 3.5M | $36.0 million | 9.83% | no change |
| Puma Biotechnology Inc. PBYI | 4.1M | $33.5 million | 9.14% | no change |
| Jade Biosciences Inc. JBIO | 986.8K | $21.9 million | 5.98% | +200.0K |
| Bicara Therapeutics Inc. BCAX | 643.4K | $19.1 million | 5.21% | -1 |
| Karyopharm Therapeutics Inc. KPTI | 1.5M | $14.8 million | 4.05% | +1.2M |
| Onkure Therapeutics Inc OKUR | 2.8M | $12.9 million | 3.53% | no change |
| Cybin Inc. HELP | 1.5M | $10.2 million | 2.78% | no change |
| Protara Therapeutics Inc. TARA | 1.8M | $6.7 million | 1.83% | no change |
| Aura Biosciences Inc. AURA | 929.1K | $6.6 million | 1.80% | +333.3K |
| Athira Pharma Inc. LONA | 634.5K | $5.8 million | 1.59% | no change |
| Verastem Inc. VSTM | 1.5M | $5.6 million | 1.53% | no change |
| Aadi Bioscience Inc. WHWK | 1.1M | $5.2 million | 1.42% | no change |
| Q32 Bio Inc. QTTB | 216.2K | $2.8 million | 0.75% | -98.9K |
| Engene Therapeut ENGN | 1.3M | $2.2 million | 0.60% | new |
| Jasper Therapeutics Inc. JSPR | 1.4M | $604,027 | 0.16% | +26.7K |
| Bioatla Inc. BCAB | 108.1K | $447,645 | 0.12% | -5.3M |
| Vyne Therapeutics Inc. VYNE | 1.4K | $926 | 0.00% | no change |